Friday , May 25 2018
Home / Therapies / DPP-4 Therapy Center (page 6)

DPP-4 Therapy Center

DPP-4 Inhibitors in Combination with Insulin Therapy for Type 2 Diabetes Patients

The addition of a DPP-4 inhibitor decreased HbA1C while not requiring an increase in insulin, and subjects remained weight neutral without experiencing an increase in hypoglycemic events… Currently approved dipeptidyl peptidase-4 (DPP-4) inhibitors include alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin. DPP-4 inhibitors work by enhancing glucose dependent insulin secretion and …

Read More »

Metformin Is Best Initial Oral Drug for Lowering Glucose Levels in Diabetes Patients

Metformin, sulfonylureas, thiazolidinedione, and DPP-4 inhibitors were compared to evaluate the effects on the time to subsequent treatment… There are many classes of oral drugs used for diabetes therapy, but there is a lack of evidence as to which drug is best for use as initial therapy. Most patients diagnosed …

Read More »

SGLT2 Inhibitors as Add-On for Poorly Controlled Patients on DPP-4s and Metformin

As the diabetes epidemic continues to grow, practitioners are increasingly searching for medication solutions that can help patients to better manage their diabetes. This month, we have a recent slides series from the ADA showing the positive effects of adding-on SGLT-2 inhibitors to the medication regimen of patients on DPP-4’s …

Read More »

Handbook of Diabetes, 4th Edition, Excerpt #10: Management of Type 2 Diabetes

handbook-of-diabetes-image

Rudy Bilous, MD, FRCP Richard Donnelly, MD, PHD, FRCP, FRACP   Lifestyle modification The starting points and mainstays of treatment for type 2 diabetes are diet and other modifications of lifestyle, such as increasing exercise and stopping smoking (Figure 11.1). The major aims are to reduce the weight of obese patients and …

Read More »

Could Glucagon-like Peptide-1 (GLP-1) Agonists Be Delivered Intranasally?

Possibility of non-subcutaneous administration could increase patient compliance….  GLP-1 agonists are effective therapeutic options for treating diabetes. While their effectiveness has been established, compliance with these medications may be limited in some patients due to their subcutaneous route of administration and gastrointestinal adverse effects. In a recent prospective, double-blind, placebo-controlled …

Read More »